Aktie A3DGDS CANBRIDGE PHARMACEUTICALS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen CANbridge Pharmaceuticals Inc.

Aktien

A3DGDS

KYG1821D1097

1228

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:05 02.07.2024 		% 5 Tage % 1. Jan.
0,32 HKD -3,03 % Intraday Chart für CANbridge Pharmaceuticals Inc. -3,03 % -67,68 %
22.04. CANbridge Pharmaceuticals Inc. gibt Ergebnisse der klinischen Phase-II-Studie mit CAN008 zur Behandlung von Glioblastoma multiforme bekannt CI
28.03. CANbridge Pharmaceuticals Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials
CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
CANbridge to Participate in Two Investor Conferences in September
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CANbridge Pharmaceuticals Releases Phase 1B Data for Red Blood Cell Disorder Treatment
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DGDS Aktie
  4. Nachrichten CANbridge Pharmaceuticals Inc.
  5. Andere Sprachen